Literature DB >> 20379806

Multiple bone lesions and hypercalcemia presented in diffuse large B cell lymphoma: mimicking multiple myeloma?

Ping Chen1, Bingzong Li, Wenzhuo Zhuang, Haiwen Huang, Hong Zhang, Jinxiang Fu.   

Abstract

We encountered a 58-year-old female patient who developed hypercalcemia and multiple bone lesions. She complained of lumbodorsal pain, nausea and vomiting on admission. Radiographic examination revealed multiple osteolytic lesions. She was diagnosed diffuse large B cell lymphoma (BLBCL) by bone marrow examination and biopsy of cervical lymph node. She underwent eight cycles of chemotherapy and is now in the stable stage. Osteogenic potential of mesenchymal stem cells from bone marrow was found to be correlated with the expression of Dickkopf1 (DKK-1) in the bone marrow plasma and lymphoma cells before and after treatment. PTH-related protein (PTHrP) expression was detectable in the lymphoma cells and was elevated in the serum. The receptor activator of nuclear factor kappaB ligand expression was found to be elevated in the bone marrow plasma and mesenchymal stem cells. These findings suggest that factors affecting the differentiation of both osteoblasts and osteoclasts involved in the pathogenesis of hypercalcemia and bone lesions of lymphoma. This was similar to that of multiple myeloma in which bone lesions and hypercalcemia are frequently observed.

Entities:  

Mesh:

Year:  2010        PMID: 20379806     DOI: 10.1007/s12185-010-0562-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  Non-Hodgkin's lymphoma presenting as multiple bone lesions and hypercalcemia.

Authors:  Hirotaka Takasaki; Heiwa Kanamori; Maki Takabayashi; Satoshi Yamaji; Hideyuki Koharazawa; Jun Taguchi; Katsumichi Fujimaki; Yoshiaki Ishigatsubo
Journal:  Am J Hematol       Date:  2006-06       Impact factor: 10.047

3.  Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.

Authors:  Hironobu Shibata; Masahiro Abe; Kenji Hiura; Javier Wilde; Keiji Moriyama; Toshiaki Sano; Ken-Ichi Kitazoe; Toshihiro Hashimoto; Shuji Ozaki; Shingo Wakatsuki; Shinsuke Kido; Daisuke Inoue; Toshio Matsumoto
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

4.  Hypercalcemia due to sun exposure in a patient with multiple myeloma and elevated parathyroid hormone-related protein.

Authors:  Peter D Papapetrou; Marina Bergi-Stamatelou; Helen Karga; Stavroula Thanou
Journal:  Eur J Endocrinol       Date:  2003-03       Impact factor: 6.664

5.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Authors:  D M Anderson; E Maraskovsky; W L Billingsley; W C Dougall; M E Tometsko; E R Roux; M C Teepe; R F DuBose; D Cosman; L Galibert
Journal:  Nature       Date:  1997-11-13       Impact factor: 49.962

Review 6.  Pathophysiology of myeloma bone disease.

Authors:  Flavia R Esteve; G David Roodman
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

7.  Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

Authors:  Martin Kaiser; Maren Mieth; Peter Liebisch; Romy Oberländer; Jessica Rademacher; Christian Jakob; Lorenz Kleeberg; Claudia Fleissner; Edgar Braendle; Malte Peters; David Stover; Orhan Sezer; Ulrike Heider
Journal:  Eur J Haematol       Date:  2008-03-10       Impact factor: 2.997

8.  Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells.

Authors:  D G Hicks; T Gokan; R J O'Keefe; S M Totterman; P J Fultz; A R Judkins; S P Meyers; D J Rubens; J Z Sickel; R N Rosier
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

9.  Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Authors:  Nicola Giuliani; Simona Colla; Vittorio Rizzoli; Sophie Barillé-Nion; Régis Bataille
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Localised lymphoma of bone: prognostic factors and treatment recommendations. The Princess Margaret Hospital Lymphoma Group.

Authors:  A J Rathmell; M K Gospodarowicz; S B Sutcliffe; R M Clark
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more
  3 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

2.  Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man.

Authors:  Hafez Mohammad Ammar Abdullah; Moataz Ellithi; Qazi Waqas; Arwyn Cunningham; Tony Oliver
Journal:  BMJ Case Rep       Date:  2019-08-04

3.  Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance.

Authors:  Jing Pan; Yuanyuan Sun; Ning Zhang; Jianming Li; Fangxin Ta; Wei Wei; Shanshan Yu; Limei Ai
Journal:  Oncol Lett       Date:  2017-07-07       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.